Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Global Sepsis Diagnosis and Treatment Report 2017 with Focus on the US - Research and Markets

Research and Markets
Posted on: 28 Aug 17

The "Sepsis - Diagnosis and Treatment Report" report has been added to Research and Markets' offering.

In 2014, US healthcare spending exceeded $3.0 trillion with nearly 1/3 spent on hospitalizations. Informed by real-world data from an Electronic Health Record (EHR) database of clinical and administrative records spanning 273 million encounters for 60 million patients in 600+ hospitals across the US, this report estimates 30% of all hospital discharges involve treatment of infectious organisms.

Sepsis is responsible for an estimated 12% of all hospital stays. At an average cost of $15,500 per occurrence, we estimate that hospitalizations for severe infections account for $212 billion in annual spending or 7% of total healthcare expenditure. In this report, we conduct an in-depth analysis of sepsis patient characteristics, medication management, costs, and laboratory testing.

Gram-positive bacteria are the likely causative agents of most sepsis infections. Physicians treat the vast majority of these infections with vancomycin, piperacillin-tazobactam, levofloxacin, and ceftriaxone. From 2010-2015, drug-resistant organisms caused an astonishing 40% of bacterial sepsis infections. After confirmatory diagnosis, over half of sepsis patients undergo a change in antibiotic therapy.

This report provides quantitative, objective data captured by hospitals contributing to Cerner Health Facts. This data provides real-world patient encounters and reflects real physician decisions and encounter characteristics (e.g. patient response to therapy and outcomes) in key areas, such as antibiotic resistant pathogens and antimicrobial stewardship.

Key Topics Covered:

1. Outline

2. Executive Summary

3. Incidence and Impact of Disease

  • Incidence
  • Length of Stay
  • Total Cost

4. Patient Demographics

  • Age
  • Insurance type
  • Gender
  • Region
  • Mortality
  • Comorbid Conditions

5. Patient Segmentation by Diagnostic Testing

Causative Etiologic Agent

6. Length of Stay and Cost by Patient Segment

  • Age at Admission
  • APACHE II Score
  • First Care Setting

7. Patient Flow through the Hospital

  • Admission Site
  • Lab Testing
  • Lab TAT
  • Results
  • Etiology
  • Empiric Therapy
  • Change in treatment

8. Drug Share for Key Therapeutics

  • Most Common
  • LOS
  • APACHE Score
  • Treatment Duration
  • Product Dashboards
    • Market Share
    • Demographics
    • Hospitalization

9. Outcomes of Treatment

  • Antibiotic Usage
  • Mortality
  • Cost per Patient

10. Drug Resistant Sepsis

  • Current Trends
  • Costs
  • Comorbidity
  • LOS
  • Mortality

11. Database Overview

12. Methodology

For more information about this report visit https://www.researchandmarkets.com/research/dl9c8k/sepsis

View source version on businesswire.com: http://www.businesswire.com/news/home/20170828005588/en/

Business Wire
www.businesswire.com

Last updated on: 28/08/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.